Real‐World Study to Evaluate Change in Clinical, Wearable Biosensor and Patient‐Reported Outcomes Among Patients With Rheumatoid Arthritis Initiating Treatment With a JAK or Tumor Necrosis Factor Inhibitor
Authors' conclusion
Treatment response is observed across diverse data types and tracking RA disease activity outside of the clinic for patients initiating new treatments may be useful in evaluating disease status and optimal changes in therapy, even in the absence of physician-derived measures.
Study context
- Population
- Patients with rheumatoid arthritis (RA) with moderate-to-high disease activity (Clinical Disease Activity Index (CDAI) >10) prescribed upadacitinib or adalimumab, 28 US community rheumatology clinics, March 2021-October 2022150 provided clinical and patient-reported outcome (PRO) data
- Participants
- 299 patients
- Outcome
- Change from baseline to follow-up in clinical, PRO and biosensor data
- Follow-up
- ≥12 weeks
Methodological detailsreal-world, multicentre (28 community rheumatology clinics), wearable biosensor (wrist-worn Fitbit), Pearson R correlations and linear regression models
- Real-world
- Multicentre (28 community rheumatology clinics)
- Wearable biosensor (wrist-worn Fitbit)
- Pearson R correlations and linear regression models
Main finding
As reported in the abstract
Mean CDAI improvement (units)
13
Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference, Fatigue and Sleep Disturbance score improvement (units)
4 to 5
Observational data: associations, not effects.
Further findings
Correlation between CDAI and PROs (Pearson R)
- Moderate correlations between CDAI and PROs
- 0.38 to 0.56
Variability in change in CDAI explained by changes in PROs (linear regression)
- Variability in CDAI change explained by PRO changes
- 52%
Biosensor data provided
- Patients of main study population providing biosensor data
- 95 (63%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →